Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507310 | 0.98 | ALDH1A1 (0.57) | ALDH1A1EPHX1CYP1A2GRM2PPARG | |
| SCHEMBL1862673 | 0.94 | — | — | |
| SCHEMBL1937353 | 0.85 | — | — | |
| SCHEMBL50924 | 0.72 | — | — | |
| SCHEMBL1682675 | 0.72 | — | — | |
| SCHEMBL5605198 | 0.72 | — | — | |
| SCHEMBL8612439 | 0.71 | ALDH1A1 (0.64) | ALDH1A1EPHX1CYP1A2GRM2PPARG | |
| SCHEMBL23495987 | 0.70 | ALDH1A1 (1.00) | ALDH1A1EPHX1CYP1A2SPHK1SPHK2 | |
| SCHEMBL12977806 | 0.70 | ALDH1A1 (1.00) | ALDH1A1EPHX1CYP1A2SPHK1SPHK2 | |
| SCHEMBL5313598 | 0.70 | ALDH1A1 (1.00) | ALDH1A1EPHX1CYP1A2SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245249-A1 | Heterocyclically Substituted Anilinopyrimidines | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | claimed |
| US-20110245249-A1 | Heterocyclically Substituted Anilinopyrimidines | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245249-A1 | Heterocyclically Substituted Anilinopyrimidines | POLL, H1-2, H1-0 | ALDH1A1 530/4885EPHX1 378/4885CYP1A2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.